Literature DB >> 23019289

Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy.

Els Van de Vijver1, Andrea Bertilde Schreuder, Wybrich Riemke Cnossen, Anna Caecilia Muller Kobold, Patrick Ferry van Rheenen.   

Abstract

BACKGROUND: Up to 70% of children and teenagers referred to a paediatric gastroenterology centre with suspected inflammatory bowel disease (IBD) do not have the disease.
OBJECTIVE: To evaluate whether faecal calprotectin as an 'add-on test' improves the specificity of the clinical case definition for suspected IBD in a general paediatric practice.
DESIGN: A prospective diagnostic accuracy study.
SETTING: Six outpatient clinics for general paediatrics and one tertiary care hospital in the Netherlands. PATIENTS: 117 children and teenagers with a clinical suspicion of IBD. DIAGNOSTIC TESTS: Faecal calprotectin was measured (index test) in all patients. Patients with a high index of suspicion on the basis of the paediatrician's global assessment, physical examination and blood results were referred for endoscopy (reference standard). Children and teenagers who were not selected for endoscopy initially were followed for half a year for the appearance of possible additional symptoms (delayed type reference standard). PRIMARY OUTCOME: The proportion of referred patients with confirmed IBD.
RESULTS: The mean age of patients was 14 years (range 6-18). A total of 42 (36%) had confirmed IBD. The paediatricians, who were blinded to the faecal calprotectin result, referred 68 children and teenagers for endoscopy. If they had referred only those patients with a positive faecal calprotectin result (>50 μg/g), 54 patients would have undergone endoscopy. LIMITATION: The study relied on clinical follow-up to detect missed IBD.
CONCLUSIONS: A diagnostic strategy in general paediatric practice of using a simple clinical case definition for suspected IBD in combination with a positive faecal calprotectin result increases the specificity to detect IBD and reduces the need for referral to a paediatric gastroenterology centre with a very low risk of missing cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23019289     DOI: 10.1136/archdischild-2011-301206

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

Review 1.  Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.

Authors:  Anna Medkova; Josef Srovnal; Jarmila Potomkova; Jana Volejnikova; Vladimir Mihal
Journal:  World J Pediatr       Date:  2018-06-01       Impact factor: 2.764

Review 2.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

3.  Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

4.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

5.  Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009.

Authors:  R Park; S Mikami; J LeClair; A Bollom; C Lembo; S Sethi; A Lembo; M Jones; V Cheng; E Friedlander; S Nurko
Journal:  Neurogastroenterol Motil       Date:  2015-03-22       Impact factor: 3.598

Review 6.  Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice.

Authors:  Eliza Lężyk-Ciemniak; Magdalena Tworkiewicz; Dominika Wilczyńska; Anna Szaflarska-Popławska; Aneta Krogulska
Journal:  Med Princ Pract       Date:  2020-10-29       Impact factor: 1.927

Review 7.  The role of calprotectin in pediatric disease.

Authors:  George Vaos; Ioannis D Kostakis; Nick Zavras; Athanasios Chatzemichael
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

8.  Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Andrew S Day; Ulrika L Fagerberg; Paul Henderson; Stevan T Leach; Gøri Perminow; David Mack; Patrick F van Rheenen; Els van de Vijver; David C Wilson; Johannes B Reitsma; Marjolein Y Berger
Journal:  JAMA Pediatr       Date:  2017-10-01       Impact factor: 26.796

9.  Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial.

Authors:  Anke Heida; Alie Dijkstra; Henk Groen; Anneke Muller Kobold; Henkjan Verkade; Patrick van Rheenen
Journal:  Trials       Date:  2015-06-16       Impact factor: 2.279

10.  Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age.

Authors:  Marta Velasco Rodríguez-Belvís; Javier Francisco Viada Bris; Carmen Plata Fernández; Alberto García-Salido; Julia Asensio Antón; Gloria Domínguez Ortega; Rosa Ana Muñoz Codoceo
Journal:  Paediatr Child Health       Date:  2019-06-17       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.